Compare Incyte Corporation (INCY) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Warner Music Group Corp — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Warner Music Group Corp trades at $28.02 (market cap $14.64B). The key difference: Incyte Corporation is the larger of the two by market cap, and Warner Music Group Corp pays a 2.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WMG | |
|---|---|---|
Market Cap | $23.11B | $14.64B |
Sector | Health | Media |
52-Week High | $118.52 | $34.72 |
52-Week Low | $67.38 | $23.65 |
Enterprise Value | $19.13B | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Warner Music Group (WMG) trades at $28.08, down 0.88% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is steady, reaching $6.71B in 2025, but net income margin has declined to 5.44%. Recent developments include a strategic renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, enhancing IP monetization capabilities in the evolving music industry.
The stock offers a 44% upside to the consensus price target of $40.40, supported by strong analyst buy ratings (66.66%), but faces risks from competitive pressures and margin compression. Investors should weigh the high P/E ratio of 33.73 against growth initiatives and cash flow improvements projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
